Curis (CRIS) Non Operating Interest Expenses (2013 - 2025)
Curis' (CRIS) quarterly Non Operating Interest Expenses came in at $314000.0 in Q4 2025, down 63.1% on a YoY basis from $851000.0 in Q4 2024, and down 64.52% quarter-over-quarter from $885000.0 in Q3 2025.
Analysis
Curis (CRIS) Non Operating Interest Expenses (2013 - 2025) Analysis & Trends
Curis (CRIS) has reported Non Operating Interest Expenses for 13 consecutive years, with $314000.0 the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Non Operating Interest Expenses fell 63.1% year-over-year to $314000.0; the trailing twelve-month figure through Jun 2026 stood at $1.2 million (down 28.93% YoY), and the FY2025 full-year result was $2.2 million, up 255.28% from the prior year.
- Non Operating Interest Expenses declined to $314000.0 in Q4 2025 per CRIS's latest filing, from $885000.0 in the prior quarter.
- Across five years, Non Operating Interest Expenses topped out at $1.7 million in Q4 2022 and bottomed at -$150000.0 in Q3 2024.
- Historically, Non Operating Interest Expenses has averaged $703100.0 across 5 years, with a median of $744500.0 in 2023.
- The sharpest annual moves came in 2024 and 2025: Non Operating Interest Expenses tumbled 124.23% in 2024, then jumped 5525.0% in 2025.
- Over 5 years, Non Operating Interest Expenses stood at $1.1 million in 2021, then soared by 49.28% to $1.7 million in 2022, then slumped by 89.22% to $178000.0 in 2023, then surged by 378.09% to $851000.0 in 2024, then plunged by 63.1% to $314000.0 in 2025.
- According to Business Quant data, Non Operating Interest Expenses over the past three periods registered $314000.0, $885000.0, and $434000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 673.00 Mn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 247.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 11.00 Mn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | -1.00 Mn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Curis | 2.57 Mn | -3.05 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 314,000.00 |
| Sep 30, 2025 | 885,000.00 |
| Jun 30, 2025 | 434,000.00 |
| Mar 31, 2025 | 552,000.00 |
| Dec 31, 2024 | 851,000.00 |
| Sep 30, 2024 | -150,000.00 |
| Jun 30, 2024 | -8,000.00 |
| Mar 31, 2024 | -78,000.00 |
| Dec 31, 2023 | 178,000.00 |
| Sep 30, 2023 | 619,000.00 |
| Jun 30, 2023 | 638,000.00 |
| Mar 31, 2023 | 584,000.00 |
| Dec 31, 2022 | 1.65 Mn |
| Sep 30, 2022 | 1.02 Mn |
| Jun 30, 2022 | 1.04 Mn |
| Mar 31, 2022 | 1.06 Mn |
| Dec 31, 2021 | 1.11 Mn |
| Sep 30, 2021 | 1.06 Mn |
| Jun 30, 2021 | 1.14 Mn |
| Mar 31, 2021 | 1.17 Mn |